Muckle-wells syndrome effectively treated with canakinumab: Is the recommended dosing schedule mandatory?

Dermatology

Volumn 223, Issue 2, 2011, Pages 113-118

  Mueller, Simon M ^a   Itin, Peter ^a   Haeusermann, Peter ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Canakinumab; Cryopyrin associated periodic fever syndrome; Economical aspects; Muckle Wells syndrome; Reflare guided

Indexed keywords

ANTIHISTAMINIC AGENT; CANAKINUMAB; CRYOPYRIN; CYCLOOXYGENASE 2; CYCLOSPORIN; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 6; MUTANT PROTEIN; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; STEROID;

ADULT; CASE REPORT; CHRONIC URTICARIA; CINCA SYNDROME; COMPARATIVE STUDY; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FAMILIAL COLD AUTOINFLAMMATORY SYNDROME; FEMALE; GASTROENTERITIS; GENE ACTIVATION; HUMAN; MALE; MONONUCLEAR PHAGOCYTE; MUCKLE WELLS SYNDROME; PREMENSTRUAL SYNDROME; PRIORITY JOURNAL; RASH; REVIEW; RHINOCONJUNCTIVITIS; RHINOPHARYNGITIS; SINGLE DRUG DOSE; TARGET CELL; URINARY TRACT INFECTION; URTICARIA; VIRUS INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; CARRIER PROTEINS; CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES; FEMALE; HUMANS; INTERLEUKIN-1BETA; MALE; MIDDLE AGED; MUTATION; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 82455212471     PISSN: 10188665     EISSN: 14219832     Source Type: Journal    
DOI: 10.1159/000331580     Document Type: Review

References (24)

1. Feist E, Burmester GR: Canakinumab for treatment of cryopyrin-associated periodic syndrome. Expert Opin Biol Ther 2010; 10: 1631-1636.
2. Cuisset L, Jeru I, Dumont B, et al: Mutations in the autoinflammatory cryopyrin-associated periodic syndrome gene: epidemiological study and lessons from eight years of genetic analysis in France. Ann Rheum Dis 2010; 70: 495-499.
3. Lainka E, Neudorf U, Lohse P, et al: Analysis of cryopyrin-associated periodic syndromes (CAPS) in German children: epidemiological, clinical and genetic characteristics. Klin Padiatr 2010; 222: 356-361.
4. Muckle TJ, Wells M: Urticaria, deafness, and amyloidosis: a new heredo-familial syndrome. Q J Med 1962; 31: 235-248.
5. Toker O, Hashkes PJ: Critical appraisal of canakinumab in the treatment of adults and children with cryopyrin-associated periodic syndrome (CAPS). Biologics 2010; 4: 131-138.
6. Hawkins PN, Lachmann HJ, Aganna E, et al: Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004; 50: 607-612. (Pubitemid 38198844)
7. Lachmann HJ, Goodman HJ, Gilbertson JA, et al: Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007; 356: 2361-2371. (Pubitemid 46883770)
8. Shinkai K, McCalmont TH, Leslie KS: Cryopyrin-associated periodic syndromes and autoinflammation. Clin Exp Dermatol 2008; 33: 1-9. (Pubitemid 350308516)
9. Kitley JL, Lachmann HJ, Pinto A, et al: Neurologic manifestations of the cryopyrinassociated periodic syndrome. Neurology 2010; 74: 1267-1270.
10. van der Hilst JC, Simon A, Drenth JP: Hereditary periodic fever and reactive amyloidosis. Clin Exp Med 2005; 5: 87-98. (Pubitemid 41597267)
11. Kolivras A, Theunis A, Ferster A, et al: Cryopyrin-associated periodic syndrome: an autoinflammatory disease manifested as neutrophilic urticarial dermatosis with additional perieccrine involvement. J Cutan Pathol 2011; 38: 202-208.
12. Haas N, Kuster W, Zuberbier T, et al: Muckle-Wells syndrome: clinical and histological skin findings compatible with cold air urticaria in a large kindred. Br J Dermatol 2004; 151: 99-104. (Pubitemid 39061285)
13. Kieffer C, Cribier B, Lipsker D: Neutrophilic urticarial dermatosis: a variant of neutrophilic urticaria strongly associated with systemic disease. Report of 9 new cases and review of the literature. Medicine (Baltimore) 2009; 88: 23-31.
14. Piram M, Frenkel J, Gattorno M, et al: A preliminary score for the assessment of disease activity in hereditary recurrent fevers: results from the AIDAI (Auto-Inflammatory Diseases Activity Index) Consensus Conference. Ann Rheum Dis 2011; 70: 309-314.
15. Hoffman HM, Mueller JL, Broide DH, et al: Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001; 29: 301-305. (Pubitemid 33096455)
16. Aksentijevich I, Nowak M, Mallah M, et al: De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrinassociated autoinflammatory diseases. Arthritis Rheum 2002; 46: 3340-3348. (Pubitemid 35453546)
17. Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al: Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009; 360: 2416-2425.
18. Lachmann HJ, Lowe P, Felix SD, et al: In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009; 206: 1029-1036.
19. European Medicines Agency: CHMP assessment report for Ilaris. 2009.
20. Health Canada: Summary Basis of Decision (SBD) Pr ILARIS. 2010.
21. Gillmore JD, Lovat LB, Persey MR, et al: Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001; 358: 24-29. (Pubitemid 32709735)
22. Kuemmerle-Deschner JB, Ramos E, Blank N, et al: Canakinumab (ACZ885, a fully human IgG1 anti-IL-1beta mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS). Arthritis Res Ther 2011; 13:R34.
23. Ruperto N, Quartier P, Wulffraat N: Evaluation of safety and preliminary efficacy of canakinumab (ACZ885), a new IL-1 beta blocking monoclonal antibody, in children with systemic juvenile idiopathic arthritis (sJIA). Arthritis Rheum 2009; 60(suppl 10): 2055.
24. Schlesinger N, De Meulemeester M, Pikhlak A, et al: Canakinumab relieves symptoms of acute flares and improves health-related quality of life in patients with difficult-totreat gouty arthritis by suppressing inflammation: results of a randomized, dose-ranging study. Arthritis Res Ther 2011; 13:R53.